ERBB2 and cancer: In addition to induction ADCC, pertuzumab also showed to inhibit HER2-positive cancer cell proliferation in the absence of immune cells, implicating the anti-cancer effects of the pertuzumab through alteration of HER2-mediated signaling pathways [22,23,24].